Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Gastrointestinal 4Gynecologic 3Breast 3Sarcoma 2NET 2Endocrine 2Thoracic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 17Melanoma 15Head and Neck Neoplasms 15Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Stomach Neoplasms 8Uterine Cervical Neoplasms 7Neoplasms 7Colorectal Neoplasms 7Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Carcinoma, Merkel Cell 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Squamous Cell 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Esophageal Neoplasms 3Urogenital Neoplasms 2Thyroid Carcinoma, Anaplastic 2Sarcoma 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Microsatellite Instability 2Mesothelioma, Malignant 2Mesothelioma 2Gastrointestinal Neoplasms 2

Interventions

pembrolizumab 12Docetaxel 7durvalumab 5Gemcitabine 5Trastuzumab 4Radiotherapy 4Surveys and Questionnaires 3Magnetic Resonance Spectroscopy 3tremelimumab 2tisotumab vedotin 2pertuzumab 2motexafin gadolinium 2cemiplimab 2X-Rays 2TH 302 2Ritonavir 2Pemetrexed 2Nivolumab 2Ipilimumab 2Interviews as Topic 2Injections 2Immunoglobulin G 2Cryosurgery 2Cisplatin 2Bortezomib 2Biopsy 2Bariatric Surgery 2zenocutuzumab 1yeast-CEA vaccine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × atezolizumab × Head & Neck × Clear all
NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Maastricht University Medical Center

Phase 1/2 Recruiting
126 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡